FDA DEVICE FACTS
Spectra Optia Apheresis System
Terumobct, Inc.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The Spectra Optia® Apheresis System has been previously cleared for therapeutic plasma exchange (TPE) and Red Blood Cell Exchange (RBCX). This 510(k) involves an expansion of the indications for use, which is reflected below in italics. Indication Statement: The Spectra Optia® Apheresis System, a blood component separator, may be used to perform therapeutic plasma exchange. The Spectra Optia® Apheresis System, a blood component separator, may be used to perform Red Blood Cell Exchange (RBCX) procedures for the transfusion management of Sickle Cell Disease in adults and children. The Spectra Optia® Apheresis System, a blood component separator, may be used to reduce White Blood Cells for patients with leukocytosis at risk of leukostasis. Compared to the predicate, COBE Spectra, the device has the same intended use as a blood component separator. The predicate COBE Spectra device was previously cleared for a specific indication of therapeutic cellular depletion. The proposed modification to the indications for use falls within the general cleared indication of the predicate device.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。